Loading
Latest filing published 13 Aug 2026 for X4 Pharmaceuticals, Inc, €95k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
All filings by John Volpone on record concern X4 Pharmaceuticals, Inc. In total, 2 filings cover trades dated from 14 August 2025 to 12 August 2026.
No open-market purchase appears, only 1 sale worth €95k. Outside the open market, there are 1 share grant. 2026 to date brings no purchases and 1 sale.
Most recently, on 13 August 2026, the filings show an open-market sale worth €95k in X4 Pharmaceuticals, Inc. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations